Carnival Corp vs Zimmer Biomet Holdings Inc — how do they compare? Carnival Corp trades at $27.96 (market cap $37.98B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.55B). The key difference: Carnival Corp is far larger — about 2× Zimmer Biomet Holdings Inc's market cap, and Carnival Corp pays the higher dividend (1.62%). Which is the better fit depends on your goals.
| CCL | ZBH | |
|---|---|---|
Market Cap | $37.98B | $18.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.99 | $107.71 |
52-Week Low | $23.89 | $79.58 |
Enterprise Value | $61.91B | $25.61B |
Dividend Yield | 1.62% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Carnival Corporation (CCL) trades at $27.75, down 4.28% today, amid a bearish technical signal. The company shows strong fundamental recovery with revenue growing from $12.2B in 2022 to $26.6B in 2025, net income turning positive to $2.76B, and positive cash flow of $727M in 2025. Recent earnings beats and a 59.57% analyst buy rating support optimism, though technical indicators show near-term pressure with support at $27.
Outlook remains positive driven by record travel demand, fleet expansion, and debt reduction, with a consensus price target of $35.18 offering 27% upside. Key risks include fuel price volatility, economic sensitivity, and execution of growth plans amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →